Company
Atavistik Bio
Harnessing the power of allostery to develop transformative medicines
Also known as Atavistik Bio, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Atavistik Bio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation of disease-causing proteins, with the potential to offer transformative treatment for patients with serious diseases.
Funding snapshot
- Total raised
- $260MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series B, $40M2026-03-05
Funding rounds
- Series B
- $40M2026-03-05, Company stated
- Series B
- $120M2025-12-18, Company stated
- Round, 2023
- $40M2023-12-19, Company stated
- Series A
- $60M2021-08-24, Company stated
Products
- Other
- ATV-1601
Loading relationship preview